Xofigo

Update on the Combination Use of Zytiga and Xofigo

Sub-group analysis of the clinical trial ERA 223 signal that the concerns about the use in combination of Zytiga and Xofigo might not cause a significant increase in the risk for developing bone fractures if a man is also simultaneously on a bone targeted therapy.

Xofigo (Radium-223) - Cautionary Information

The European Medicines Agency (EMA) has recommended that the use of Xofigo (Radium-223) be restricted.  The restrictions, because of safety and efficacy concerns in men with castrate resistant prostate cancer (mCRPC), include that Xofigo can be used only after two other treatments have been taken; when other therapies cannot be used and not in combination with other 2nd line hormone therapies. 

Comparing the Efficacy of the Treatment Options of Metastatic, Castration-Resistant, Docetaxel-Resistant Prostate Cancer

There was a large meta-analysis recently published that compared the efficacy of abiraterone acetate (Zytiga), enzalutamide (Xtandi), cabazitaxel (Jevtana) and Radium-223 (Xofigo) in the treatment of castration-resistant, docetaxel-resistant metastatic prostate cancer.

Warning - A Possible Danger - Xofigo in Combination with Zytiga and Prednisone

The European Medicines Agency (EMA) has recommended halting the use of the Xofigo (radium-223 dichloride) in combination with Zytiga (abiraterone acetate) and prednisone due to a possible increased risk of death and fractures.

Xofigo Probably Can Be Used More Than Once

Early results from an international, open-label, phase 1/2 trial (NCT01934790) showed that it is possible to successfully re-treat men with the drug known as Xofigo (Ra-223).  The study found that when used a second time, Xofigo was well tolerated and that it provides favorable effects on the cancer’s progression.